Evaluating measured structural failure endpoints from Level I/II randomized clinical trials and defining the patient risk stratification framework (ROHI criteria) for biological augmentation.
Human Dermal Allograft (hADM) is supported by Level I randomized trials (Barber et al.), demonstrating an absolute structural re-tear reduction of >26% in large tears (>3 cm) compared to unaugmented repairs. Conversely, 1st-generation porcine SIS xenografts yielded high structural failures (~42%) due to severe non-infectious sterile synovitis (Iannotti et al.).
Surgeons do not routinely augment small (1.5 cm) tears. Augmentation is indicated when the Rotator Cuff Healing Index (ROHI) identifies compromised intrinsic biology: retracted tears ≥3 cm, Goutallier grade ≥2 fatty infiltration, patient age >65, or revision repair. Mechanical footprint compression alone reaches a biological limit in these cohorts.